{
    "guideline": {
        "id": "PA166119846",
        "name": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
        "source": "CPIC",
        "version": 45,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166119846",
        "relatedChemicals": [
            {
                "id": "PA449211",
                "name": "dapsone",
                "symbol": null
            },
            {
                "id": "PA450457",
                "name": "methylene blue",
                "symbol": null
            },
            {
                "id": "PA165963961",
                "name": "pegloticase",
                "symbol": null
            },
            {
                "id": "PA10176",
                "name": "rasburicase",
                "symbol": null
            },
            {
                "id": "PA166115580",
                "name": "tafenoquine",
                "symbol": null
            },
            {
                "id": "PA166268821",
                "name": "toluidine blue",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA28469",
                "name": "glucose-6-phosphate dehydrogenase",
                "symbol": "G6PD"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166298576",
            "name": "Recommendation PA166298576",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA166268821",
                    "name": "toluidine blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061178,
                "html": "<p>No reason to avoid based on G6PD status</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Toluidine blue classification strength is based on extrapolation from methylene blue data</p>\n"
            },
            "implications": [
                "G6PD: Low risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Normal"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297619",
            "name": "Recommendation PA166297619",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA10176",
                    "name": "rasburicase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060221,
                "html": "<p>No reason to avoid based on G6PD status</p>\n"
            },
            "implications": [
                "G6PD: Low risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Normal"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297579",
            "name": "Recommendation PA166297579",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA449211",
                    "name": "dapsone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060181,
                "html": "<p>Avoid use</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Deficient"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298519",
            "name": "Recommendation PA166298519",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA166115580",
                    "name": "tafenoquine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061121,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n"
            },
            "implications": [
                "G6PD: Unknown risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297611",
            "name": "Recommendation PA166297611",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA449211",
                    "name": "dapsone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060213,
                "html": "<p>No reason to avoid based on G6PD status</p>\n"
            },
            "implications": [
                "G6PD: Low risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Normal"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297615",
            "name": "Recommendation PA166297615",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA165963961",
                    "name": "pegloticase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060217,
                "html": "<p>Avoid use</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Deficient"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298241",
            "name": "Recommendation PA166298241",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450457",
                    "name": "methylene blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060843,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute exacerbation of chronic hemolysis"
            ],
            "lookupKey": {
                "G6PD": "Deficient with CNSHA"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297620",
            "name": "Recommendation PA166297620",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA10176",
                    "name": "rasburicase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060222,
                "html": "<p>Avoid use</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Deficient"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297580",
            "name": "Recommendation PA166297580",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA449211",
                    "name": "dapsone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060182,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute eacerbation of chronic hemolysis"
            ],
            "lookupKey": {
                "G6PD": "Deficient with CNSHA"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298242",
            "name": "Recommendation PA166298242",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450457",
                    "name": "methylene blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060844,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I\u2013III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.</p>\n"
            },
            "implications": [
                "G6PD: Variable risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Variable"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298515",
            "name": "Recommendation PA166298515",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA166115580",
                    "name": "tafenoquine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061117,
                "html": "<p>No reason to avoid based on G6PD status</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Tafenoquine\u2019s safety has been established for a G6PD enzyme activity \u226570% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity \u226570%.)</p>\n"
            },
            "implications": [
                "G6PD: Low risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Normal"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297612",
            "name": "Recommendation PA166297612",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA449211",
                    "name": "dapsone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060214,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I\u2013III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.</p>\n"
            },
            "implications": [
                "G6PD: Variable risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Variable"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297616",
            "name": "Recommendation PA166297616",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA165963961",
                    "name": "pegloticase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060218,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute eacerbation of chronic hemolysis"
            ],
            "lookupKey": {
                "G6PD": "Deficient with CNSHA"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298239",
            "name": "Recommendation PA166298239",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450457",
                    "name": "methylene blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060841,
                "html": "<p>No reason to avoid based on G6PD status</p>\n"
            },
            "implications": [
                "G6PD: Low risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Normal"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298569",
            "name": "Recommendation PA166298569",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA166268821",
                    "name": "toluidine blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061171,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I\u2013III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases. Toluidine blue classification strength is based on extrapolation from methylene blue data</p>\n"
            },
            "implications": [
                "G6PD: Variable risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Variable"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297621",
            "name": "Recommendation PA166297621",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA10176",
                    "name": "rasburicase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060223,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute eacerbation of chronic hemolysis"
            ],
            "lookupKey": {
                "G6PD": "Deficient with CNSHA"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298543",
            "name": "Recommendation PA166298543",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA166268821",
                    "name": "toluidine blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061145,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Toluidine blue classification strength is based on extrapolation from methylene blue data</p>\n"
            },
            "implications": [
                "G6PD: Unknown risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297613",
            "name": "Recommendation PA166297613",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA449211",
                    "name": "dapsone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060215,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n"
            },
            "implications": [
                "G6PD: Unknown risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298243",
            "name": "Recommendation PA166298243",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450457",
                    "name": "methylene blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060845,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n"
            },
            "implications": [
                "G6PD: Unknown risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297622",
            "name": "Recommendation PA166297622",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA10176",
                    "name": "rasburicase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060224,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I\u2013III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.</p>\n"
            },
            "implications": [
                "G6PD: Variable risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Variable"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298516",
            "name": "Recommendation PA166298516",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA166115580",
                    "name": "tafenoquine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061118,
                "html": "<p>Avoid use</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Deficient"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297617",
            "name": "Recommendation PA166297617",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA165963961",
                    "name": "pegloticase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060219,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I\u2013III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.</p>\n"
            },
            "implications": [
                "G6PD: Variable risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Variable"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298534",
            "name": "Recommendation PA166298534",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA166268821",
                    "name": "toluidine blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061136,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals. Toluidine blue classification strength is based on extrapolation from methylene blue data</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute exacerbation of chronic hemolysis"
            ],
            "lookupKey": {
                "G6PD": "Deficient with CNSHA"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298518",
            "name": "Recommendation PA166298518",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA166115580",
                    "name": "tafenoquine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061120,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I\u2013III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases. Tafenoquine\u2019s safety has been established for a G6PD enzyme activity \u226570% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity \u226570%.)</p>\n"
            },
            "implications": [
                "G6PD: Variable risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Variable"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298509",
            "name": "Recommendation PA166298509",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA166268821",
                    "name": "toluidine blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061111,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Toluidine blue classification strength is based on extrapolation from methylene blue data</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Deficient"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297614",
            "name": "Recommendation PA166297614",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA165963961",
                    "name": "pegloticase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060216,
                "html": "<p>No reason to avoid based on G6PD status</p>\n"
            },
            "implications": [
                "G6PD: Low risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Normal"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166297623",
            "name": "Recommendation PA166297623",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA10176",
                    "name": "rasburicase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060225,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n"
            },
            "implications": [
                "G6PD: Unknown risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298517",
            "name": "Recommendation PA166298517",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA166115580",
                    "name": "tafenoquine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061119,
                "html": "<p>Avoid use</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute exacerbation of chronic hemolysis"
            ],
            "lookupKey": {
                "G6PD": "Deficient with CNSHA"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166297618",
            "name": "Recommendation PA166297618",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA165963961",
                    "name": "pegloticase",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060220,
                "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n"
            },
            "implications": [
                "G6PD: Unknown risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298240",
            "name": "Recommendation PA166298240",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450457",
                    "name": "methylene blue",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060842,
                "html": "<p>Avoid use</p>\n"
            },
            "implications": [
                "G6PD: High risk of acute hemolytic anemia"
            ],
            "lookupKey": {
                "G6PD": "Deficient"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        }
    ],
    "citations": [
        {
            "pmid": "36049896",
            "title": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.",
            "authors": [
                "Gammal Roseann S",
                "Pirmohamed Munir",
                "Somogyi Andrew A",
                "Morris Sarah A",
                "Formea Christine M",
                "Elchynski Amanda L",
                "Oshikoya Kazeem A",
                "McLeod Howard L",
                "Haidar Cyrine E",
                "Whirl-Carrillo Michelle",
                "Klein Teri E",
                "Caudle Kelly E",
                "Relling Mary V"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2022
        },
        {
            "pmid": "24787449",
            "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.",
            "authors": [
                "Relling M V",
                "McDonagh E M",
                "Chang T",
                "Caudle K E",
                "McLeod H L",
                "Haidar C E",
                "Klein T",
                "Luzzatto L",
                "Clinical Pharmacogenetics Implementation Consortium"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2014
        }
    ],
    "version": "2024-03-25-16-13"
}